IGC vs IMMX

IGC Pharma, Inc. vs Immix Biopharma, Inc. — Valuation Comparison 2026

IGC

Biotechnology
IGC Pharma, Inc.
Quality
5.4
out of 10
Value Trap
38
LOW
Price
$0.29
Last close
Models
11/13
Active
VS

IMMX

Biotechnology
Immix Biopharma, Inc.
Quality
5.1
out of 10
Value Trap
30
LOW
Price
$8.84
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType IGC Fair ValueIGC Upside IMMX Fair ValueIMMX Upside
Bayesian DCF Intrinsic $0.08 -73.3% $2.98 -66.3%
Earnings Power Value Intrinsic $0.09 -72.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.11 -62.2% $1.23 -86.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IGC vs IMMX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IGC vs IMMX — Which Stock Is More Undervalued?

IGC scores higher with a 5.4/10 quality rating vs IMMX's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IGC Pharma, Inc. (IGC) and Immix Biopharma, Inc. (IMMX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IGC currently trades at $0.29 with a QOC of 5.4/10, while IMMX trades at $8.84 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).